Oncology Venture – Latest news

Subscribe for news from Oncology Venture here

subscribe

 

 

 

Duncan Moore presents Oncology Venture

See the video (Click the picture)

 

Oncology Venture: Notice to attend Annual General Meeting 30 May 2018 to approve the merger plans with Medical Prognosis Institute

English
Swedish

 

Read the merger plan and all documents related to the AGM and the merger between Oncology Venture and Medical Prognosis Institute

All documents related to the AGM
The merger plan between OV-MPI

 

OV announces merger plans between Oncology Venture and Medical Prognosis Institute

English
Swedish

 

Read the merger prospectus

English
Swedish

 

OV announces positive interim results from a phase 2 study with LiPlaCis and its DRP in heavily pretreated metastatic breast cancer patients

English
Swedish

 

Read article about Oncology Venture from Børsen

Danish

 

Oncology Venture will execute license to multi TKI phase 3 compound

English
Swedish

 

Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor from Eisai

 

 

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

See Press release
Läs pressmeddelande

 

Successful prediction of Cancer response to LiPlaCis in Breast cancer and other tumors by OV’s DRP

See Press release
Läs pressmeddelande

 

2X Oncology obtains US IND for 2X-111 a Liposomal doxorubicin

See Press release
Läs pressmeddelande

 

The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by the DRP

See Press release
Läs pressmeddelande

 

Latest articles from MedWatch (Danish)

11 April 2018: Oncology Venture acquires rights to shelved Novartis drug
28 March: Incitamentsprogrammer giver biotekselskab røde tal på bundlinjen
14 March 2018: Danish biotech merger to attract major investors
6 February: Oncology Venture udnævner ny finansdirektør
2 February 2018: Biotek-boss om nye studiedata: “Det største i Oncology Ventures historie”
8 January 2018: Finansdirektør køber aktier for 560.000 kr i dansk biotekselskab
27 December 2017: Oncology Venture får grønt lys til nyt forsøg
1 December 2017: Oncology Venture fremlægger milliontab og beder markedet om penge
17 November 2017: Oncology Venture forlænger option på Novartis-middel
7 August 2017: Oncology Venture indgår aftale med japansk lægemiddelgigant
3 August 2017: Lovende studie bringer Oncology Venture nærmere første lægemiddel
27 Juni 2017: MPI vil rejse millioner til udvikling af medicinvælger
31 May 2017: Oncology Venture kører i stilling til knoglemarvskræft-studie
19 May 2017: MPI-test skal sparke nyt liv i gammel kemoterapi
24 March 2017: Oncology Venture indgår aftale med japanske Eisai
15 February 2017: Oncology Venture vil hente rekordbeløb
19 January 2017: Oncology Venture får europæisk stjernebevilling